Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Renal_cell_carcinoma
gptkb:Serous_carcinoma |
| gptkbp:associated_with |
ovary
cellular metabolism hypoxia kidney inflammation tumor heterogeneity tumor microenvironment angiogenesis metastasis diagnostic challenges clinical symptoms endometrium immune evasion survivorship issues epithelial-mesenchymal transition paraneoplastic syndromes treatment challenges stem cell properties |
| gptkbp:clinical_trial |
ongoing trials
combination therapy studies immunotherapy studies targeted therapy studies |
| gptkbp:features |
gptkb:physicist
chromosomal instability PBR M1 mutation SET D2 mutation VHL mutation |
| gptkbp:grades |
high grade
low grade |
| https://www.w3.org/2000/01/rdf-schema#label |
clear cell carcinoma
|
| gptkbp:number_of_stages |
stage I
stage IV stage II stage III |
| gptkbp:research_focus |
biomarkers
patient outcomes novel therapies treatment resistance genetic profiling |
| gptkbp:risk_factor |
hypertension
obesity family history smoking |
| gptkbp:social_responsibility |
variable
imaging studies biopsy more common in adults more common in men incidence increasing |
| gptkbp:symptoms |
abdominal pain
hematuria |
| gptkbp:treatment |
gptkb:hospital
radiation therapy chemotherapy recurrence possible survival rates vary variable response to treatment |